Open Access

Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma

  • Authors:
    • Peng Zhou
    • Xuemin Li
  • View Affiliations

  • Published online on: May 7, 2019     https://doi.org/10.3892/ol.2019.10331
  • Pages: 307-313
  • Copyright: © Zhou et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

The aim of the present study was to investigate the expression of microRNA (miR)‑338‑5p in retinoblastoma(RB), thereby evaluating whether it could have potential as a biomarker to screen patients with RB from healthy controls. The results revealed that miR‑338‑5p was significantly upregulated in patients with RB compared with in healthy controls. There was no significant difference in the expression of miR‑338‑5p between patients with RB of different age, sex, tumor stage or binocular disease. Receiver operator characteristic analysis indicated that serum miR‑338‑5p combined with neuron‑specific enolase (NSE) had a larger area under the curve compared with serum miR‑338‑5p alone when diagnosing RB. In addition, suppression of miR‑338‑5p induced slower proliferation of ACBRI‑181 and Y79 cells at 2, 3, 4 and 5 days compared with the negative control group. Flow cytometric analysis indicated that transfection with miR‑338‑5p inhibitor leads to significant cell cycle arrest in ACBRI‑181 and Y79 cells compared with in the negative control group. Furthermore, transfection with miR‑338‑5p inhibitor significantly decreased ACBRI‑181 and Y79 cell migration and invasion, suggesting that miR‑338‑5p may serve an oncogenic role in the progression of RB. In conclusion, the low expression of miR‑338‑5p in the serum of patients with RB suggests that it may be involved in the formation of RB. Serum miR‑338‑5p has the potential to be a tumor marker of RB, and, in combination with NSE, miR‑338‑5p may improve the early diagnosis rate of RB.
View Figures
View References

Related Articles

Journal Cover

July-2019
Volume 18 Issue 1

Print ISSN: 1792-1074
Online ISSN:1792-1082

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Zhou P and Zhou P: Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma. Oncol Lett 18: 307-313, 2019
APA
Zhou, P., & Zhou, P. (2019). Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma. Oncology Letters, 18, 307-313. https://doi.org/10.3892/ol.2019.10331
MLA
Zhou, P., Li, X."Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma". Oncology Letters 18.1 (2019): 307-313.
Chicago
Zhou, P., Li, X."Serum miR‑338‑5p has potential for use as a tumor marker for retinoblastoma". Oncology Letters 18, no. 1 (2019): 307-313. https://doi.org/10.3892/ol.2019.10331